MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574086 | Name: Sennoside B
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sennoside B is a glycoside that has laxative and gastroprotective activities. It inhibits H+/K+-ATPase activity and increases levels of prostaglandin E2 (PGE2). Sennoside B increases the intestinal transport rate by 72.2% but has no effect on the rate of gastric emptying. It reduces HCl/ethanol-induced gastritis and indomethacin-induced gastric ulcers and may be used in the treatment of constipation.

Chemical Structure

Sennoside B
CAS#128-57-4

Theoretical Analysis

MedKoo Cat#: 574086

Name: Sennoside B

CAS#: 128-57-4

Chemical Formula: C42H38O20

Exact Mass: 862.1956

Molecular Weight: 862.75

Elemental Analysis: C, 58.47; H, 4.44; O, 37.09

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,150.00 2 Weeks
1g USD 3,250.00 2 Weeks
2g USD 5,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Sennoside B; SennosideB; Sennoside-B
IUPAC/Chemical Name
(9R,9'S)-4,4'-dihydroxy-10,10'-dioxo-5,5'-bis(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-9,9',10,10'-tetrahydro-[9,9'-bianthracene]-2,2'-dicarboxylic acid
InChi Key
IPQVTOJGNYVQEO-AIFLABODSA-N
InChi Code
InChI=1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58)/t23-,24-,25-,26+,31-,32-,35+,36+,37-,38-,41-,42-/m1/s1
SMILES Code
[H][C@@]1([C@](C2=C(C3=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=CC=C2)(C5=C3C(O)=CC(C(O)=O)=C5)[H])C6=C(C(C7=C1C=CC=C7O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)=O)C(O)=CC(C(O)=O)=C6
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway.
In vitro activity:
Sennoside B is therefore of potential utility in the treatment of proliferative diseases in which platelet-derived growth factor (PDGF) signaling plays a central role. In human MG63 osteosarcoma cells, sennoside B was found to inhibit PDGF-BB-induced phosphorylation of the PDGF receptor. Sennoside B binded directly to the extracellular domains of both PDGF-BB and the PDGF-beta receptor. Sennoside B also inhibited PDGF-BB stimulation of MG63 cell proliferation. Reference: Life Sci. 2009 Jun 19;84(25-26):915-22. https://pubmed.ncbi.nlm.nih.gov/19393247/
In vivo activity:
In a rat model of pentylenetetrazole-induced seizures, sennoside B could potentially be a candidate for epilepsy management, without serious side effects. The seizure spike percentage was significantly lower in groups that received sennoside B. The RCS score was lower and the FJM onset time was higher in the sennoside B-administered groups. Brain MDA and brain aquaporin-3 levels were lower and brain SOD activity was higher in the sennoside-administered groups. Reference: Hum Exp Toxicol. 2023 Jan-Dec;42:9603271231168764. https://pubmed.ncbi.nlm.nih.gov/37021362/
Solvent mg/mL mM comments
Solubility
DMF 15.0 17.39
DMSO 2.0 2.32
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 862.75 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhang DW, Xu XS, Zhou R, Fu Z. Modulation of HIV-1 capsid multimerization by sennoside A and sennoside B via interaction with the NTD/CTD interface in capsid hexamer. Front Microbiol. 2023 Sep 25;14:1270258. doi: 10.3389/fmicb.2023.1270258. PMID: 37817748; PMCID: PMC10561090. 2. Chen YC, Chang CN, Hsu HC, Chiou SJ, Lee LT, Hseu TH. Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells. Life Sci. 2009 Jun 19;84(25-26):915-22. doi: 10.1016/j.lfs.2009.04.003. Epub 2009 Apr 22. PMID: 19393247. 3. Sahin H, Erbaş O. Beneficial effects of sennoside B on pentylenetetrazole-induced seizures in rats. Hum Exp Toxicol. 2023 Jan-Dec;42:9603271231168764. doi: 10.1177/09603271231168764. PMID: 37021362. 4. Zhang D, Huang D, Ji Y, Jiang C, Li Y, Gao M, Yao N, Liu X, Shao H, Jing S, Ni Y, Yin Z, Zhang J. Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent. J Drug Target. 2015 Feb;23(2):180-90. doi: 10.3109/1061186X.2014.971328. Epub 2014 Oct 20. PMID: 25330022.
In vitro protocol:
1. Zhang DW, Xu XS, Zhou R, Fu Z. Modulation of HIV-1 capsid multimerization by sennoside A and sennoside B via interaction with the NTD/CTD interface in capsid hexamer. Front Microbiol. 2023 Sep 25;14:1270258. doi: 10.3389/fmicb.2023.1270258. PMID: 37817748; PMCID: PMC10561090. 2. Chen YC, Chang CN, Hsu HC, Chiou SJ, Lee LT, Hseu TH. Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells. Life Sci. 2009 Jun 19;84(25-26):915-22. doi: 10.1016/j.lfs.2009.04.003. Epub 2009 Apr 22. PMID: 19393247.
In vivo protocol:
1. Sahin H, Erbaş O. Beneficial effects of sennoside B on pentylenetetrazole-induced seizures in rats. Hum Exp Toxicol. 2023 Jan-Dec;42:9603271231168764. doi: 10.1177/09603271231168764. PMID: 37021362. 2. Zhang D, Huang D, Ji Y, Jiang C, Li Y, Gao M, Yao N, Liu X, Shao H, Jing S, Ni Y, Yin Z, Zhang J. Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent. J Drug Target. 2015 Feb;23(2):180-90. doi: 10.3109/1061186X.2014.971328. Epub 2014 Oct 20. PMID: 25330022.
1. Franz, G. The senna drug and its chemistry. Pharmacology 47(Suppl 1), 2-6 (1993). 2. Hwang, I.Y., and Jeong, C.S. Gastroprotective activities of sennoside A and sennoside B via the up-regulation of prostaglandin E2 and the inhibition of H+/K+-ATPase. Biomol. Ther. (Seoul) 23(5), 458-464 (2015).